Zacks: Analysts Expect Nurix Therapeutics, Inc. (NASDAQ:NRIX) Will Post Quarterly Sales of $9.98 Million

Last updated on Saturday, April 24, 2021 | 2021 MarketBeat

Brokerages predict that Nurix Therapeutics, Inc. (NASDAQ:NRIX) will post $9.98 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for Nurix Therapeutics' earnings. The lowest sales estimate is $5.26 million and the highest is $14.70 million. The company is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Nurix Therapeutics will report full year sales of $43.91 million for the current year, with estimates ranging from $35.01 million to $50.11 million. For the next financial year, analysts forecast that the firm will report sales of $65.53 million, with estimates ranging from $62.25 million to $68.80 million. Zacks' sales calculations are an average based on a survey of sell-side analysts that cover Nurix Therapeutics.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Monday, April 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.45) by ($0.18).

A number of research firms have issued reports on NRIX. Zacks Investment Research cut shares of Nurix Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, April 17th. Needham & Company LLC reiterated a "buy" rating and issued a $44.00 target price on shares of Nurix Therapeutics in a research note on Wednesday, February 17th. Piper Sandler increased their target price on shares of Nurix Therapeutics from $40.00 to $60.00 and gave the company an "overweight" rating in a research note on Wednesday, February 17th. Berenberg Bank assumed coverage on shares of Nurix Therapeutics in a research note on Tuesday. They issued a "buy" rating for the company. Finally, JPMorgan Chase & Co. increased their target price on shares of Nurix Therapeutics from $34.00 to $56.00 and gave the company an "overweight" rating in a research note on Friday, January 29th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Nurix Therapeutics presently has an average rating of "Buy" and a consensus price target of $46.80.

NRIX stock opened at $30.62 on Friday. Nurix Therapeutics has a 52-week low of $15.21 and a 52-week high of $52.38. The company has a 50-day moving average of $33.52 and a two-hundred day moving average of $35.08.

In other news, CFO Houte Hans Van sold 5,330 shares of the firm's stock in a transaction that occurred on Monday, February 22nd. The shares were sold at an average price of $39.93, for a total transaction of $212,826.90. Following the completion of the sale, the chief financial officer now owns 1,417 shares of the company's stock, valued at $56,580.81. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, General Counsel Christine Ring sold 1,200 shares of the firm's stock in a transaction that occurred on Monday, April 12th. The stock was sold at an average price of $27.20, for a total transaction of $32,640.00. Following the sale, the general counsel now directly owns 2,005 shares of the company's stock, valued at approximately $54,536. The disclosure for this sale can be found here. Insiders sold 18,430 shares of company stock valued at $623,987 in the last three months.

Several hedge funds and other institutional investors have recently bought and sold shares of NRIX. BlackRock Inc. increased its holdings in shares of Nurix Therapeutics by 74.7% during the fourth quarter. BlackRock Inc. now owns 1,169,974 shares of the company's stock worth $38,470,000 after buying an additional 500,176 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in shares of Nurix Therapeutics during the third quarter worth approximately $2,521,000. Nuveen Asset Management LLC increased its holdings in shares of Nurix Therapeutics by 47.9% during the fourth quarter. Nuveen Asset Management LLC now owns 98,841 shares of the company's stock worth $3,250,000 after buying an additional 31,991 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Nurix Therapeutics by 5.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 591,636 shares of the company's stock valued at $19,453,000 after purchasing an additional 28,890 shares in the last quarter. Finally, Swiss National Bank acquired a new stake in shares of Nurix Therapeutics in the fourth quarter valued at approximately $825,000. 81.99% of the stock is owned by institutional investors.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Featured Story: Why are percentage decliners important?

Get a free copy of the Zacks research report on Nurix Therapeutics (NRIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nurix Therapeutics (NASDAQ:NRIX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: Stock Market - What is a circuit breaker?



7 Undervalued Stocks That Deserve More Attention

With the Dow Jones Industrial Average (DJIA) hitting new highs seemingly every day, it may seem like the wrong time to be looking at undervalued stocks. Or is it?

From cannabis to cryptocurrencies, and let’s not forget electric vehicles the market seems to be blowing bubbles wherever you look. And that’s why now may be exactly the right time to zig while the market is sagging. And that means looking for undervalued stocks.

But finding undervalued stocks is subjective. Some analysts use specific fundamental metrics. Others use technical analysis.

However, the general idea is that you’re looking for stocks that are trading below their fair value.

In some cases, these may be stocks whose financials are stronger than other stocks in their sector, but it’s trading at a lower price. In other cases, a company may have potential that is not reflected in its stock price. Put another way, undervalued stocks are stocks that have room to grow. That’s why they deserve a place in your portfolio.

And that’s why we’ve put together this special presentation on stocks that are undervalued right at this time. An investment in these companies is likely to be rewarded because the stocks are moving under the radar from the broader market.

View the "7 Undervalued Stocks That Deserve More Attention".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.